Drug reference
maxacalcitol
Vitamin D analogue
Vitamin D analogue
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Differs from calcitriol only in the substitution of C-22 with an O atom. It has a low affinity for vitamin D–binding protein, leading to more free (unbound) drug. It is a potent suppressor of PTH gene expression and shows very limited activity on intestine and bone.
Indications
secondary hyperparathyroidism in patients with chronic kidney disease (CKD)
Pharmacokinetics
Half-life
shorter than calcitriol
Related guidelines
Chronic kidney disease — assessment and management
KDIGO · Nephrology · 2024
Chronic kidney disease — assessment and management
NICE · Nephrology · 2021
Chronic kidney disease — mineral and bone disorder
KDIGO · Nephrology · 2017
Diabetes management in chronic kidney disease
KDIGO · Nephrology · 2022
Hypertension in chronic kidney disease
KDIGO · Nephrology · 2021
Other Vitamin D analogue drugs
Ask House about maxacalcitol
Continue into a citation-backed clinical answer with the drug context already attached.
Textbook-sourced·Sources: Goodman & Gilman 14e·Updated: 2026-05-10